Jeff Yass’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $89.4K | Sell |
28,015
-20,657
| -42% | -$83.8K | ﹤0.01% | 12572 |
|
|
2026
Q1 | $215K | Buy |
48,672
+2,307
| +5% | +$12.5K | ﹤0.01% | 11551 |
|
|
2025
Q4 | $295K | Sell |
46,365
-14,066
| -23% | -$97.9K | ﹤0.01% | 9984 |
|
|
2025
Q3 | $564K | Sell |
60,431
-48,101
| -44% | -$486K | ﹤0.01% | 8694 |
|
|
2025
Q2 | $1.56M | Buy |
108,532
+40,279
| +59% | +$398K | ﹤0.01% | 6327 |
|
|
2025
Q1 | $471K | Sell |
68,253
-4,354
| -6% | -$27.4K | ﹤0.01% | 9022 |
|
|
2024
Q4 | $385K | Buy |
72,607
+1,198
| +2% | +$6.56K | ﹤0.01% | 9291 |
|
|
2024
Q3 | $261K | Buy |
+71,409
| New | +$225K | ﹤0.01% | 9905 |
|
|
2024
Q2 | – | Sell |
-269,603
| Closed | -$902K | – | 13430 |
|
|
2024
Q1 | $938K | Buy |
269,603
+253,219
| +1,546% | +$469K | ﹤0.01% | 7073 |
|
|
2023
Q4 | $23.4K | Buy |
+16,384
| New | +$22.8K | ﹤0.01% | 11944 |
|
|
2023
Q2 | – | Sell |
-108,947
| Closed | -$167K | – | 13345 |
|
|
2023
Q1 | $167K | Buy |
+108,947
| New | +$194K | ﹤0.01% | 10809 |
|
|
2022
Q4 | – | Sell |
-95,620
| Closed | -$118K | – | 13921 |
|
|
2022
Q3 | $118K | Sell |
95,620
-145,008
| -60% | -$233K | ﹤0.01% | 11544 |
|
|
2022
Q2 | $402K | Buy |
240,628
+198,402
| +470% | +$388K | ﹤0.01% | 8800 |
|
|
2022
Q1 | $104K | Sell |
42,226
-2,784
| -6% | -$7.61K | ﹤0.01% | 11880 |
|
|
2021
Q4 | $168K | Buy |
45,010
+17,970
| +66% | +$97K | ﹤0.01% | 11664 |
|
|
2021
Q3 | $170K | Sell |
27,040
-66,479
| -71% | -$548K | ﹤0.01% | 11670 |
|
|
2021
Q2 | $922K | Sell |
93,519
-257,292
| -73% | -$2.24M | ﹤0.01% | 7993 |
|
|
2021
Q1 | $3.28M | Buy |
350,811
+324,679
| +1,242% | +$2.57M | ﹤0.01% | 4766 |
|
|
2020
Q4 | $125K | Buy |
26,132
+8,890
| +52% | +$43.3K | ﹤0.01% | 10372 |
|
|
2020
Q3 | $69K | Sell |
17,242
-11,368
| -40% | -$54.8K | ﹤0.01% | 10098 |
|
|
2020
Q2 | $131K | Buy |
28,610
+15,692
| +121% | +$70.3K | ﹤0.01% | 9354 |
|
|
2020
Q1 | $42K | Buy |
+12,918
| New | +$49.6K | ﹤0.01% | 9748 |
|
|
2019
Q4 | – | Sell |
-28,470
| Closed | -$101K | – | 10826 |
|
|
2019
Q3 | $112K | Buy |
28,470
+6,199
| +28% | +$26.4K | ﹤0.01% | 9499 |
|
|
2019
Q2 | $104K | Buy |
+22,271
| New | +$95K | ﹤0.01% | 9588 |
|
|
2018
Q3 | – | Sell |
-14,886
| Closed | -$55K | – | 10413 |
|
|
2018
Q2 | $55K | Sell |
14,886
-203,153
| -93% | -$772K | ﹤0.01% | 9249 |
|
|
2018
Q1 | $916K | Buy |
218,039
+193,241
| +779% | +$1.01M | ﹤0.01% | 5435 |
|
|
2017
Q4 | $146K | Sell |
24,798
-8,164
| -25% | -$44.1K | ﹤0.01% | 8504 |
|
|
2017
Q3 | $142K | Sell |
32,962
-68,119
| -67% | -$249K | ﹤0.01% | 8227 |
|
|
2017
Q2 | $386K | Buy |
+101,081
| New | +$320K | ﹤0.01% | 7123 |
|
|
2017
Q1 | – | Sell |
-56,866
| Closed | -$188K | – | 10158 |
|
|
2016
Q4 | $188K | Buy |
+56,866
| New | +$155K | ﹤0.01% | 8691 |
|
|
2016
Q3 | – | Sell |
-12,427
| Closed | -$45.6K | – | 9170 |
|
|
2016
Q2 | $51K | Buy |
+12,427
| New | +$58.8K | ﹤0.01% | 8235 |
|
Other funds holding NAGE
SW
TCM
Jeff Yass's NAGE Position: Q2 2026 in Review
Jeff Yass reduced its Niagen Bioscience (NAGE) stake by 42% in Q2 2026, selling an estimated $83.8K and leaving 28,015 shares worth $89.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12572.
Jeff Yass first reported a position in NAGE in Q2 2016 and has held it in 31 quarters since. The position peaked at $3.28M in Q1 2021. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Jeff Yass held 28,015 shares of Niagen Bioscience worth $89.4K as of Q2 2026.
- Jeff Yass sold 20,657 Niagen Bioscience shares in Q2 2026, an estimated $83.8K.
- Niagen Bioscience made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12572 holding.
- Jeff Yass first reported a position in Niagen Bioscience in Q2 2016 and has held it in 31 quarters since.
- Jeff Yass's Niagen Bioscience position peaked at $3.28M in Q1 2021.
- 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.